Sinopharm Group Co. Ltd.
http://ir.sinopharmgroup.com.cn/html/index.php
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sinopharm Group Co. Ltd.
Asia Deal Watch: Astellas Seeks Pantherna’s Assistance On mRNA-Based Regenerative Medicine
Plus deals involving OliPass/Vanda, Simcere/Almirall, Sinopharm/Merck & Co., Jiuzhou/Sandoz, Zai Lab/Seagen, Sciwind/SynderK, Hansoh/KiOmed.
'COVID Zero' Weakening Immune Systems? Flu Outbreaks Hit China
China reports flu outbreaks as COVID-19 cases decline, suggesting that population immunity may have been affected by the country's strict "COVID Zero" policies. The cost and availability of flu vaccines in the country are other policy factors playing into the situation.
Beijing Expands COVID Testing; Stringent New COVID Policy Coming?
Beijing expands mass testing to more areas and Shanghai’s case fatally rate raises questions amid China deals with the worst outbreak in two years.
Boosters Miss Growth Expectations Despite China COVID Surge
While two Chinese companies gained domestic approvals for their recombinant protein and adenovirus-based COVID-19 shots as heterologous boosters in February, these currently only account for roughly 21% of all booster shots, showing the continued predominance of inactivated virus-based technology in the country.
Company Information
- Industry
- Distributors
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Vaccines
- Other Names / Subsidiaries
-
- China National Medical Device Co., Ltd. (CMIC)
- China National Pharmaceutical Industry Co., Ltd. (Sinopharm CNPIC)
- China National Scientific Instruments & Materials Corporation (Sinopharm CSIMC)
- China Sinopharm International Corporation (Sinopharm International)
- Sinopharm A-THINK Pharmaceutical Co., Ltd
- Sinopharm Group Company Limited